Sign In
Buy BLU
$14.74
+0 (+0%)
At Close: Sep 27, 2023
Biopharma stock soars on takeover deal plus more daily small cap and micro cap movers
03:06pm, Tuesday, 18'th Apr 2023
11:55am: Bellus Health (TSX:BLU), The Lion Electric Company shares make big gains BELLUS Health Inc (Bellus Health (TSX:BLU)) shares shot up 99% to $19.33 on Tuesday after the late-stage biopharma
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
12:11pm, Tuesday, 18'th Apr 2023
LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based,
Why BELLUS Health Stock Is Rocketing Higher Today
11:33am, Tuesday, 18'th Apr 2023
BELLUS Health and GSK have agreed on a $2 billion buyout agreement. Through this deal, GSK will acquire a late-stage chronic cough medication that could be worth billions in peak sales.
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
09:56am, Tuesday, 18'th Apr 2023
GSK added to a series of recent takeovers Tuesday with the $2 billion acquisition of Bellus Health. But BLU stock and GSK stock diverged.
Bellus Health's stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss
08:31am, Tuesday, 18'th Apr 2023
Here are some of the biggest movers on Tuesday:
GSK pays £1.6bn for Canada's Bellus Health
02:48am, Tuesday, 18'th Apr 2023
GSK PLC (LSE:GSK, NYSE:GSK) has paid around £1.6bn for Bellus Health (TSX:BLU) Inc, a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments. The pharmaceutica
GSK to acquire U.S.-based BELLUS Health for $14.75 per share
02:33am, Tuesday, 18'th Apr 2023
GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company Bellus Health Inc. BLU, +3.08% BLU, +2.83% for $14.75 a share in cash, representing a total equity
Wall Street Analysts Think Bellus (BLU) Could Surge 156.01%: Read This Before Placing a Bet
11:27am, Friday, 24'th Mar 2023
The mean of analysts' price targets for Bellus (BLU) points to a 156% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
Bellus Health: Building Momentum Around CALM, SOOTHE Studies
12:56pm, Friday, 23'rd Dec 2022
Refractory chronic cough remains as a complex condition that requires a medical breakthrough for treatment. BELLUS Health Inc. is pushing ahead on this front, with recent support from evidence in its
Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Monday, 14'th Nov 2022
Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?
11:18am, Tuesday, 11'th Oct 2022
Here is how Bellus Health (BLU) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
07:00am, Monday, 10'th Oct 2022
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr
Bellus: Expected Phase 3 Start Makes This A Long-Term Play
02:34pm, Wednesday, 07'th Sep 2022
BELLUS Health intends to initiate two phase 3 studies in Q4 of 2022; these will be CALM-1 and CALM-2 studies using BLU-5937 for treatment of patients with refractory chronic cough. Final results from
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr
Why BELLUS Health Stock Fell Today
12:02pm, Thursday, 14'th Jul 2022
Issuing new shares will leave it with plenty of money in the bank.
